PDPK1 and neoplasm: Using a genome-wide lentiviral small hairpin RNA library screen, the PDPK1 inhibitor BX-795 has been shown to significantly reduce tumor-specific cell growth and synergize with docetaxel to enhance treatment sensitivity in prostate cancer cells [30].